The Role of GABAB Receptor Mechanisms in Cough: Effect of Lesogaberan, Baclofen and Placebo on Experimentally Induced Cough Responses in Healthy Controls

niversity Hospital of South Manchester NHS Foundation Trust (UK)0 个研究点目标入组 15 人开始时间: 2014年2月25日最近更新: 2017年4月3日

适应症

试验速览

暂无简介。

•1. Provision of signed, written and dated informed consent, prior to any study-specific procedures
•2. Aged 18 to 70 years
•3. Body mass index (BMI) of between 19 and 30 kg/m2 (inclusive) and weight between 50 kg and 100 kg
•4. Normal spirometry
•5. Clinically normal physical findings
•6. Subjects with no concurrent diseases who do not require any medication
•7. Female subjects with no childbearing potential or using highly effective method of contraception for at least the previous 3 months
•Target Gender: Male & Female; Upper Age Limit 70 years ; Lower Age Limit 18 years

•1. History of any clinically significant disease or disorder, in particular no current or past history of chronic cough or respiratory disease.
•2. History or presence of gastrointestinal, hepatic or renal disease
•3. Any clinically significant illness, medical or surgical procedure or trauma within 4 weeks of the first administration of study medication
•4. Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results Abnormal screening laboratory values in Liver Function tests
•5. History of clinically significant orthostatic reaction or syncope
•6. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG according to the investigator
•7. Prolonged QTcF>450ms or family history of long QT syndrome

发起方

niversity Hospital of South Manchester NHS Foundation Trust (UK)